MedTrace Logo

TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI

NCT02018055 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2590

Last updated 2021-04-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of clopidogrel in stabilized patients with acute myocardial infarction (AMI) who performed percutaneous coronary intervention (PCI) with drug-eluting stents (DES) compared with ticagrelor.

In this study, 2,590 patients with AMI who underwent PCI with DES and took dual antiplatelet therapy as aspirin and ticagrelor during 1 month from index PCI will be randomized to aspirin+ticagrelor versus aspirin+ clopidogrel during 11 months.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Aspirin+Ticagrelor

Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)

DRUG

Aspirin+Clopidogrel

Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)

Sponsors & Collaborators

  • Chonnam National University Hospital

    collaborator OTHER

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Kiyuk Chang, MD, PhD · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-14
Primary Completion
2021-01-21
Completion
2021-01-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018055 on ClinicalTrials.gov